All articles by
Alkermes Completes Sale of Athlone, Ireland Facility to Novo Nordisk
Alkermes has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In…
Boehringer Ingelheim gets FDA approval for high-concentration formulation of Cyltezo
Boehringer Ingelheim has secured the US Food and Drug Administration (FDA) approval for the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm),…
BioCardia’s CardiAMP Cell Therapy shows patient benefits in chronic myocardial ischemia trial
BioCardia, an American regenerative medicine company, said that its CardiAMP Cell Therapy has shown patient benefits in key outcomes of…
Poolbeg Pharma Announces Significant POLB 001 Patent Granted in USA
Poolbeg Pharma, a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet…
FDA approves Lupkynis label update with AURORA programme long-term data
Aurinia Pharmaceuticals said that the US Food & Drug Administration (FDA) has approved a label update for Lupkynis (Voclosporin) to…
Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
Newron Pharmaceuticals, a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and…
Enlaza Therapeutics Raises $100m through Its Series A Financing, Led by the Life Sciences Group of J.P. Morgan Private Capital
Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be…
Tivdak gets FDA full approval for recurrent or metastatic cervical cancer
The US Food and Drug Administration (FDA) has granted full approval to Pfizer and Genmab’s Tivdak (tisotumab vedotin-tftv) to treat…
Enhertu improves PFS in Phase 3 metastatic HR+/HER2-low breast cancer trial
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has improved the progression-free survival (PFS) in DESTINY-Breast06 Phase 3 trial of patients…
X4 Pharmaceuticals gets FDA nod for Xolremdi capsules for WHIM syndrome
X4 Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for Xolremdi (mavorixafor) capsules to treat patients…